This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.
First clinical trials in children of a meningococcal meningitis vaccine began last month in Connecticut.The vaccine has been found safe and effective in adults during two years of large-scale testing at Army recruit camps. It is specifically effective against type C, one of the three major groups of meningococci.About 60 patients at Newington Children's Hospital, Newington, Conn, are receiving the vaccine. Trials are being conducted by Irving Goldschneider, MD, co-developer of the vaccine and assistant professor of pathology at the University of Connecticut Health Center, Farmington.The vaccine, and a similar one against type A, were developed at Walter Reed Army Institute of Research, Washington, DC. Co-developers are Malcolm S. Artenstein, MD, chief of the Institute's Bacteriology Department and a key figure in development of a rubella vaccine, and Emil C. Gotschlich, MD, now at Rockefeller University, New York city. Drs. Goldschneider and Gotschlich are former
Internal at large medicine. Arch Intern Med. 1970;125(3):411-422. doi:10.1001/archinte.1970.00310030015002